Assessing efficacy in early-phase cancer prevention clinical trials: The case of Ki-67 in the lung

Cancer Prevention Research

Volumn 3, Issue 2, 2010, Pages 128-131

  Szabo, Eva ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GLUTATHIONE; KI 67 ANTIGEN; LIPID; RETINOID; TRANSFORMING GROWTH FACTOR BETA;

ADENOCARCINOMA; ADENOMATOUS POLYP; ANTIGEN EXPRESSION; APOPTOSIS; BRONCHUS MUCOSA; CANCER INCIDENCE; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CANCER TISSUE; CELL ADHESION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COLORECTAL CARCINOMA; DRUG EFFICACY; DRUG MEGADOSE; EARLY CANCER; EARLY INTERVENTION; GENE EXPRESSION; GLUTATHIONE METABOLISM; HUMAN; IMMUNE RESPONSE; LEUKOPLAKIA; LIPID METABOLISM; LUNG CANCER; LUNG CARCINOGENESIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SMOKING; SMOKING CESSATION; TUMOR SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; KI-67 ANTIGEN; LUNG NEOPLASMS; PYRAZOLES; RESPIRATORY MUCOSA; SULFONAMIDES; TUMOR MARKERS, BIOLOGICAL;

EID: 77949742701     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0268     Document Type: Review

References (23)

1. Szabo E. Selecting targets for cancer prevention: where do we go from here? Nat Rev Cancer 2006;6:867-74.
2. Schatzkin A, Gail M. The promise and peril of surrogate end points in cancer research. Nature Rev 2002;2:1-9.
3. Lippman SM, Lee JS, Lotan R, Hittelman W, Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990;82:555-60.
4. Szabo E. Assessing efficacy in early-phase cancer prevention trials: the case of oral premalignancy. Cancer Prev Res 2009;1:312-5.
5. Kim ES, Hong WK, Lee JJ, et al. Biologic activity of celecoxib in the bronchial epithelium of current and former smokers. Cancer Prev Res 2010;3:148-59.
6. Szabo E. Lung epithelial proliferation: a biomarker for chemoprevention trials? J Natl Cancer Inst 2001;93:1042-3.
7. Szabo E. Proliferative changes in chemoprevention trials: learning from secondary end points. J Natl Cancer Inst 2007;99:1565-7.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
9. Marin B, Paesmans M, Mascaux C, et al. Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer 2004;91:2018-25.
10. Lee JJ, Liu D, Lee JS, et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 2001;93:1081-8.
11. Meert A-P, Feoli F, Martin B, et al. Ki67 expression in bronchial preneoplastic lesions and carcinoma in situ defined according to the new 1999 WHO/IASLC criteria: a preliminary study. Histopathology 2004;44:47-53.
12. Lapperre TS, Sont JK, van Schadewijk A, et al. Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Resp Res 2007;8:85.
13. Ayers MM, Jeffery PK. Proliferation and differentiation in mammalian airway epithelium. Eur Respir J 1988;1:58-80.
14. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323-9.
15. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality. Ann Intern Med 2005;142:233-9.
16. Miller YE, Blatchford P, Hyun DS, et al. Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary disease. Cancer Epidemiol Biomarkers Prev 2007;16:2425-31.
17. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 2006;12: 314-20.
18. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
19. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-41.
20. Hittelman WN, Liu DD, Kurie JM, et al. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 2007;99:1603-12.
21. Auman JT, Church R, Lee S-Y, Watson MA, Fleshman JW, Mcleod HL. Celecoxib pre-treatment in human colorectal adenocarcinoma patients is associated with gene expression alterations suggestive of diminished cellular proliferation. Eur J Cancer 2008;44:1754-60.
22. Sooriakumaran P, Macanas-Pirard P, Bucca G, et al. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics 2009;6:93-100.
23. Glebov O, Rodriguez LM, Lynch P, et al. Celecoxib treatment alters the gene expression profile of normal colonic mucosa. Cancer Epidemiol Biomarkers Prev 2006;15:1382-91.